Unlock new possibilities with Starpharma's cutting-edge DEP® drug delivery platform through strategic partnerships, collaborations, and licensing. Our technology, validated in clinical trials and backed by an extensive intellectual property portfolio, has the potential to significantly enhance the therapeutic and commercial value of many drugs, including oncology chemotherapeutics, non-oncology molecules, antibody-drug conjugates (ADCs), and radiotheranostics.

• Innovative Technology: Our DEP® platform employs dendrimers to improve drug performance, efficacy, and safety, enabling targeted and precisely controlled administration.
• Intellectual Property: Generate new IP and extend the patent life of drugs through our technology.
• Clinically Validated Technology: More than 350 patients have been treated with Starpharma’s DEP® drug delivery technology across multiple clinical programs.
• Collaborative Research: Access our DEP® platform for performance improvement through collaborative research and licensing agreements.
• Proven Partnerships: We have established successful partnerships with leading pharmaceutical companies and research institutes.

Contact our Business Development team at busdev@starpharma.com to find out more about partnering and how our dendrimer technology can benefit your research program.

• Clinically validated: Proven efficacy in pharmaceutical applications, including oncology.
• Precise manufacturing, characterization and scale-up: Ensures reliability and scalability.
• Targeted delivery: Allows preferential accumulation in target areas.
• Flexible pharmacokinetics (PK) management: Customize PK and biodistribution properties of drugs to enhance and preserve efficacy while minimising toxicity.
• Enhanced drug:antibody ratios (DAR): Achieve therapeutics with high DARs in a single conjugation step not possible with established ADC approaches.
• Customizable options: Tailor payload, linker and dendrimer size for novel therapy approaches.
• Depth of experience: Over 20 years leading dendrimer technology, translating discovery and research into clinical and commercial products.

Select Your Partnership Model

Choose the right partnership model for your research, whether it’s accessing our research-ready DEP® dendrimers compatible with a range of targeting moieties, a research collaboration, or a platform license.

Our Partnership Models

Optimize and Test

Investigate how increased payloads, customized pharmacokinetics (PK) and biodistribution can improve efficacy and reduce toxicity in your drug delivery program.

Collaborate with Our Experts

Work alongside Starpharma’s experienced team to refine and scale your approach, ensuring seamless progression from research to GMP production.

Advance Your Drug Development

Leverage our deep expertise to accelerate your path from concept to commercialization while enhancing your Intellectual Property (IP) portfolio.

• Biotechnology companies
• Academic institutions
• Investment and Venture Capital firms
• mAb developers
• ADC specialists
• CDMOs
• Companies focused on 505(b)(2) formulations
• Drug delivery and target discovery companies
• Developers of novel chemotherapeutic payloads

Book a consultation call by emailing busdev@starpharma.com. Let’s explore how Starpharma can elevate your research.